My Top 3 Biotech Stocks for May 2026

With stabilizing interest rates and increased FDA activity, three biotech companies stand out: Schrödinger combines AI-driven drug discovery with established software revenue ($256M in 2025); Sarepta generates nearly $2B in annual product revenue from gene therapy despite ongoing safety concerns around Elevidys; and NRX Pharmaceuticals, a speculative small-cap, has regulatory momentum with FDA decisions expected this summer for depression and suicidality treatments.

05/20/2026, 11:15 AM • The Motley Fool

Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment

The global protein synthesis research market is experiencing accelerating growth driven by increased investment in cell and gene therapy research, rising chronic disease prevalence, and expanding healthcare budgets. North America leads with 42.8% market share, while Asia-Pacific infrastructure expansion presents significant growth opportunities. Key market drivers include strong late-stage therapy pipelines and government support through initiatives like the CHIPS and Science Act.

05/18/2026, 2:33 PM • GlobeNewswire

Nasdaq 100 Enters Correction As 30-Year Yields Near 5%: What's Moving Markets Friday?

U.S. equities tumbled to their lowest levels in nearly seven months on Friday as the Nasdaq 100 officially entered correction territory, down over 10% from January highs. The decline was driven by geopolitical tensions with Iran rejecting ceasefire options, surging crude oil prices, deteriorating consumer sentiment, and rising inflation expectations. The 30-year Treasury yield climbed to 4.958%, threatening to breach 5% for the first time since July 2025, while the Fed rate hike probability by December jumped to nearly 50%.

03/27/2026, 1:09 PM • Benzinga

Stock Market Today: Dow Futures Gain, S&P 500 Slips As Investors Brace For Mega-Cap Earnings— Brand Engagement, Nucor In Focus (UPDATED)

U.S. stock futures declined on Monday as investors await mega-cap earnings from tech giants and other major companies. The market is also bracing for the Federal Reserve's interest rate decision on Wednesday, with markets pricing in a 97.2% likelihood of unchanged rates. Key movers include Baker Hughes (up on strong Q4 results), Sarepta Therapeutics (up on trial completion), and Brand Engagement Network (surging 221% on strategic partnership announcement). Analyst Mohamed El-Erian highlights the '2025 Paradox' of resilient markets amid geopolitical tensions.

01/26/2026, 8:41 AM • Benzinga

Stock Market Today: Dow Jones, S&P 500 Futures Slip As Investors Brace For Mega-Cap Earnings—Brand Engagement, Nucor In Focus

U.S. stock futures declined on Monday as investors await mega-cap earnings from tech giants and other major companies. The S&P 500, Dow Jones, and Nasdaq 100 all posted modest losses in premarket trading. Key economic events this week include the Federal Reserve's interest rate decision on Wednesday and major corporate earnings reports. Gold prices surged near record highs while crude oil and Bitcoin traded lower.

01/26/2026, 5:36 AM • Benzinga

2 Beaten-Down Stocks That Could Sink Even More in 2026

Sarepta Therapeutics and Teladoc Health are identified as two stocks likely to continue declining in 2026. Sarepta faces significant headwinds from safety concerns with its flagship DMD treatment Elevidys, which caused patient deaths and led to restricted access. Teladoc Health struggles with slowing revenue growth, mounting losses, and increased competition in the telemedicine space, particularly affecting its BetterHelp platform.

01/21/2026, 10:30 PM • The Motley Fool

Silver Breaks Above $70, Novo Nordisk Soars 9% On Obesity Pill Approval: What's Moving Markets Tuesday? (CORRECTED)

Wall Street traded modestly higher Tuesday with the S&P 500 up 0.4% near 6,900. Strong U.S. GDP data (4.3% annualized growth) prompted traders to scale back Fed rate cut expectations. Novo Nordisk surged 9% following FDA approval of Wegovy in pill form. Precious metals rallied significantly, with silver jumping over 2% to break above $70/ounce (up 140% YTD), gold reaching record highs, and platinum surging 5.5%.

12/24/2025, 9:14 AM • Benzinga

Silver Breaks Above $70, Novo Nordisk Soars 9% On Obesity Pill Approval: What's Moving Markets Wednesday?

Wall Street traded modestly higher Wednesday with the S&P 500 up 0.4% near 6,900, buoyed by stronger-than-expected U.S. GDP growth of 4.3%. Novo Nordisk surged 9% following FDA approval of Wegovy in pill form. Precious metals extended historic rallies, with silver breaking above $70 (up 140% YTD), gold reaching record highs, and platinum surging 5.5% to 2008 levels.

12/23/2025, 1:18 PM • Benzinga

Sarepta Stock Dumps: Pharma Bro Martin Shkreli Still Likes It

Sarepta Therapeutics experienced a significant stock drop of over 33% after its Phase 3 ESSENCE study for Duchenne muscular dystrophy treatments failed to meet primary endpoints, raising concerns about its drug pipeline and gene therapy safety.

11/04/2025, 12:11 PM • Benzinga

AAV Gene Therapy Market Size to Skyrocket at 40.1% CAGR by 2034

The AAV gene therapy market is projected to grow from $3.85 billion in 2025 to $78.56 billion by 2034, with a 40.1% CAGR. North America leads the market, driven by research investments, technological advancements, and increasing genetic disorder prevalence.

10/07/2025, 11:00 AM • GlobeNewswire

2 Beaten-Down Stocks to Avoid Right Now

The article analyzes two healthcare stocks, Teladoc and Sarepta Therapeutics, highlighting significant challenges that make them unattractive investment options, including revenue decline, profitability issues, and safety concerns with medical treatments.

09/05/2025, 9:30 AM • The Motley Fool

SRPT Stock Alert: Investors with Large Losses Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Sarepta Therapeutics, Inc. Class Action

Sarepta Therapeutics faces a class action lawsuit alleging misleading investors about safety risks of its ELEVIDYS gene therapy for Duchenne muscular dystrophy, with two patient deaths and FDA investigation leading to significant stock price drops.

08/29/2025, 3:13 PM • GlobeNewswire

Genetic Material Market Size, Trends and Top Companies (2025 – 2034 Forecast Period)

The genetic material market is expected to experience substantial growth driven by advancements in gene therapies, personalized medicine, and biopharmaceutical research. North America leads the market in 2024, with Asia Pacific projected to be the fastest-growing region from 2025-2034.

08/28/2025, 11:00 AM • GlobeNewswire

SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is pursuing a class action lawsuit against Sarepta Therapeutics for allegedly making false and misleading statements about its ELEVIDYS therapy's safety, potential, and revenue outlook between June 2023 and June 2025.

08/25/2025, 3:10 AM • Benzinga

SRPT FINAL DEADLINE ALERT: Hagens Berman Urges Sarepta Investors to Act Before August 25 Deadline in Securities Class Action

Sarepta Therapeutics faces a securities class-action lawsuit over safety concerns and regulatory setbacks for its gene therapy ELEVIDYS, including two patient deaths and European regulatory rejection.

08/23/2025, 4:48 PM • GlobeNewswire